Skip to main content
Zhejiang Hisoar Pharmaceutical Co.,Ltd. logo

Zhejiang Hisoar Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 002099 ISIN · CNE000001PY2 LEI · 3003009H2CTRCTXDSA42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,074 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002099

About Zhejiang Hisoar Pharmaceutical Co.,Ltd.

https://www.hisoar.com

Zhejiang Hisoar Pharmaceutical Co., Ltd. specializes in the research, development, and large-scale manufacturing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company is a prominent global supplier of antibiotic products, particularly the clindamycin series, and maintains a significant portfolio in cardiovascular, anti-diabetic, and central nervous system therapeutic areas. Beyond its proprietary product lines, the company provides comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its advanced production facilities and rigorous quality management systems. Its operations adhere to international regulatory standards, including those set by the FDA and EDQM, facilitating its role as a key partner for global pharmaceutical enterprises. The company emphasizes technological innovation and process optimization to ensure high-quality chemical synthesis and pharmaceutical production.

Recent filings

Filing Released Lang Actions
关于参投公司创新药注射用重组巴曲酶获得药物临床试验批准通知书的自愿性信息披露公告
Regulatory Filings Classification · 75% confidence The document is a voluntary corporate disclosure announcing that an investee’s innovative drug received clinical trial approval from China’s NMPA. It contains no financial statements, earnings metrics, or corporate governance materials, nor is it a notice of dividends, share changes, or legal proceedings. It is a regulatory update/miscellaneous announcement, fitting the fallback category for general regulatory notices (RNS).
2026-05-22 Chinese
关于为合并报表范围内子公司提供担保的进展公告
Capital/Financing Update Classification · 80% confidence The document is a formal corporate announcement detailing the progress of a financial guarantee provided by Zhejiang Haixiang Pharmaceutical Co., Ltd. to its consolidated subsidiary, including contract signing details, guarantee amount, and cumulative external guarantees. It does not present full financial statements, nor is it reporting on earnings, share transactions, board changes, or legal proceedings. Instead, it relates directly to the company’s financing support activities (guarantees), which falls under updates on financing activities or capital structure changes. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-05-22 Chinese
关于2020年员工持股计划存续期提示性公告
Regulatory Filings Classification · 72% confidence The document is an official announcement (‘提示性公告’) by Zhejiang Haixiang Pharmaceutical Co., Ltd. regarding the continuation and expiry terms of its 2020 employee share ownership plan. It does not present full financial statements, earnings data, or detailed governance charters but rather provides regulatory disclosure of a corporate employee share plan under CSRC and Shenzhen Stock Exchange rules. It is neither an annual/interim report, call transcript, AGM material, nor a specific remuneration report. This type of announcement falls under general regulatory filings that do not fit a more specific category.
2026-05-19 Chinese
浙江天册律师事务所关于浙江海翔药业股份有限公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a law firm’s legal opinion (“法律意见书”) on the convening, attendance, procedures, and voting at the company’s 2025 Annual General Meeting. It includes the detailed agenda items and full voting results for each proposal. This fits the category “Declaration of Voting Results & Voting Rights Announcements (Code: DVA)”, which covers official results from shareholder votes at any general meeting.
2026-05-19 Chinese
重大事项内部报告制度（2025年10月修订）
Governance Information Classification · 95% confidence The document is titled '重大事项内部报告制度' which translates to 'Major Matters Internal Reporting System' and details the internal procedures and responsibilities for reporting significant company events within Zhejiang Haixiang Pharmaceutical Co., Ltd. It outlines the scope of major matters, reporting obligations, and internal management processes. There is no financial data, earnings information, or external disclosures such as annual or quarterly reports. The content is focused on internal governance and compliance procedures related to information disclosure and reporting of significant events. This aligns with Governance Information (CGR) as it details the company's internal rules and governance practices regarding major event reporting and information disclosure.
2025-10-28 Chinese
提名委员会议事规则（2025年10月修订）
Governance Information Classification · 95% confidence The document is titled '提名委员会议事规则' which translates to 'Nomination Committee Meeting Rules' and details the rules, composition, responsibilities, and procedures of the company's nomination committee. It focuses on governance structure, board member selection, and committee operations. There is no financial data, earnings information, or report publication mentioned. The content aligns with internal governance practices and board committee rules rather than financial reporting or announcements. Therefore, the document fits best under Governance Information (CGR). The document length is 2128 characters, which is relatively short but contains substantive governance content, not just an announcement or summary.
2025-10-28 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.